Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Zimolo Z, Wesolowski G, Rodan AG: Acid extrusion is induced by osteoclast attachment to bone. J Clin Invest 1995, 96:2277-2283. Osteoclasts plated on bone acquire the capacity for Na1-independent H1 extrusion. This property is inhibited in a dose-dependent manner by preincubating the bone with alendronate or by the addition of sCT to the culture media.
Yamamoto M, Seedor JG, Rodan GA, Balena R: Endogenous calcitonin attenuates prathyroid hormone-induced cancellous bone loss in the rat. Endocrinology 1995, 136:788-795.
Baumann BD, Wronski TH: Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovarlectomized rats. Bone 1995, 16:247-253.
Plosker GL, McTavish D: Intranasal salcatonin: a review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drug Aging 1996, 8:378-400. An extensive review of the pharmacologic properties and role of intranasal salmon calcitonin in the management of postmenopausal osteoporosis with 146 updated references.
Tagliaro F, Dorizzi R, Luisetto G: Effect of antibodies to calcitonin on the pharmacokinetics and the pharmacodynamics of the hormone. Horm Metab Res 1995, 27:31-34.
Takahashi S, Goldring S, Katz M, Hilsenbeck S, Williams R, Roodman GD: Down-regulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 1995, 95:167-171.
McSheehy PMJ, Farina C, Airaghi R, Allievi E, Banfi S, Bertolini D, Ferni G, Frattola D, Oneta S, Pinza M, Sorini C, Valente M, Volontieri A: Pharmacologic evaluation of the calcitonin analogue SB205614 in models of osteoclastic bone resorption in vitro and in vivo: comparison with salmon calcitonin and elcatonin. Bone 1995, 16:435-444.
Azria M, Copp DH, Zanelli JM: Twenty-five years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 1995, 57:405-408.
Reginster JY, Meurmans L, Deroisy R, Jupsin I, Biquet I, Albert A, Franchimont P: A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994, 24:565-569.
Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, De Longueville M, Franchimont P: A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995, 98:452-458. A double blind, placebo-controlled, randomized study in which 251 healthy women were treated with two intermittent dose-regimens of nasal salmon calcitonin or placebo for 2 years.
Lyritis G, Magiasis B, Tsakalakos N: Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment Calcif Tissue Int 1995, 56:38-41.
Regisster JY, Jupsin I, Deroisy R, Biquet I, Franchimont N, Franchimont P: Prevention of postmenopausal bone loss by rectal calcitonin. Calcif Tissue Int 1995, 56:539-542.
Reginster JY: Calcitonin for prevention and treatment of osteoporosis. Am J Med 1993, 95:44-47.
Rico H, Revilla M, Hernandez ER, Villa LF, Alvarez De Buergo M: Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995, 56:181-185.
Overgaard K, Lindsay R, Christiansen C: Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study. Clin Ther 1995, 17:680-685.
Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F: Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 1995, 57:15-19.
Canatan D, Akar N, Arcasoy A: Effects of calcitonin therapy on osteoporosis in patients with thalassemia. Acta Haematol 1995, 93:20-24.
